189,041 Shares in Anavex Life Sciences Corp. $AVXL Purchased by Nuveen LLC

Key Points

• Nuveen LLC has acquired 189,041 shares of Anavex Life Sciences Corp., amounting to a value of approximately $1,622,000, representing about 0.22% of the company’s stock.
• Other institutional investors, including Vermillion Wealth Management and Raymond James Financial, have also made recent investments in Anavex, contributing to a total of 31.55% institutional ownership in the company.
• Anavex's stock has experienced a boost of 4.6%, with analysts giving it a consensus rating of "Buy" and an average target price of $44.00.

Nuveen LLC acquired a new stake in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 189,041 shares of the biotechnology company's stock, valued at approximately $1,622,000. Nuveen LLC owned about 0.22% of Anavex Life Sciences as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in AVXL. LPL Financial LLC grew its holdings in shares of Anavex Life Sciences by 482.1% during the first quarter. LPL Financial LLC now owns 546,626 shares of the biotechnology company's stock valued at $4,690,000 after purchasing an additional 452,723 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Anavex Life Sciences by 4.7% during the first quarter. Vanguard Group Inc. now owns 4,902,246 shares of the biotechnology company's stock valued at $42,061,000 after purchasing an additional 221,802 shares during the last quarter. Private Advisor Group LLC grew its holdings in shares of Anavex Life Sciences by 617.5% during the first quarter. Private Advisor Group LLC now owns 214,725 shares of the biotechnology company's stock valued at $1,842,000 after purchasing an additional 184,800 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Anavex Life Sciences by 197.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 248,139 shares of the biotechnology company's stock valued at $2,129,000 after purchasing an additional 164,792 shares during the last quarter. Finally, Swiss National Bank acquired a new position in shares of Anavex Life Sciences during the first quarter worth approximately $1,411,000. 31.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wall Street Zen downgraded Anavex Life Sciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 23rd. HC Wainwright reiterated a "buy" rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research report on Friday, August 22nd. Finally, D. Boral Capital reiterated a "buy" rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research report on Wednesday, August 27th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $44.00.

Anavex Life Sciences Stock Down 1.6%

Shares of Anavex Life Sciences stock traded down $0.15 during midday trading on Thursday, hitting $9.36. The company's stock had a trading volume of 844,453 shares, compared to its average volume of 909,570. The firm has a market capitalization of $803.93 million, a P/E ratio of -16.42 and a beta of 0.83. The stock has a 50-day simple moving average of $10.54 and a 200-day simple moving average of $9.28. Anavex Life Sciences Corp. has a 1-year low of $4.93 and a 1-year high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03). As a group, sell-side analysts predict that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.